已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes

医学 内科学 2型糖尿病 临床试验 胰高血糖素样肽1受体 糖尿病 二肽基肽酶-4 安慰剂 不利影响 梅德林 内分泌学 受体 兴奋剂 替代医学 病理 政治学 法学
作者
Peter Hanlon,Elaine Butterly,Lili Wei,Heather Wightman,Saleh Ali M. Almazam,Khalid Alsallumi,Jamie Crowther,Ryan McChrystal,Heidi Rennison,Katherine Hughes,Jim Lewsey,Robert S. Lindsay,Stuart J. McGurnaghan,John L. Petrie,Laurie A. Tomlinson,Sarah H. Wild,Amanda Adler,Naveed Sattar,David Phillippo,Sofia Dias
出处
期刊:JAMA [American Medical Association]
被引量:1
标识
DOI:10.1001/jama.2024.27402
摘要

Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex. Objective To assess whether age or sex are associated with differences in the efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors. Data Sources and Study Selection The MEDLINE and Embase databases and US and Chinese clinical trial registries were searched for articles published from inception to November 2022; in August 2024, the search was updated to capture the trial results. Two reviewers screened for randomized clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP4 inhibitors vs a placebo or active comparator in adults with type 2 diabetes. Data Extraction and Synthesis Individual participant data and aggregate data were used to estimate age × treatment interactions and sex × treatment interactions in multilevel network meta-regression models. Main Outcome and Measures Hemoglobin A 1c (HbA 1c ) and MACEs. Results Of the 601 eligible trials identified (592 trials with 309 503 participants reported HbA 1c ; mean age, 58.9 [SD, 10.8] years; 42.3% were female and 23 trials with 168 489 participants reported MACEs; mean age, 64.0 [SD, 8.6] years; 35.3% were female), individual participant data were obtained for 103 trials (103 reported HbA 1c and 6 reported MACEs). The use of SGLT2 inhibitors (vs placebo) was associated with less HbA 1c lowering with increasing age for monotherapy (absolute reduction [AR], 0.24% [95% credible interval {CrI}, 0.10% to 0.38%] per 30-year increment in age), for dual therapy (AR, 0.17% [95% CrI, 0.10% to 0.24%]), and for triple therapy (AR, 0.25% [95% CrI, 0.20% to 0.30%]). The use of GLP-1 receptor agonists was associated with greater HbA 1c lowering with increasing age for monotherapy (AR, −0.18% [95% CrI, −0.31% to −0.05%] per 30-year increment in age) and for dual therapy (AR, −0.24% [95% CrI, −0.40% to −0.07%]), but not for triple therapy (AR, 0.04% [95% CrI, −0.02% to 0.11%]). The use of DPP4 inhibitors was associated with slightly better HbA 1c lowering in older people for dual therapy (AR, −0.09% [95% CrI, −0.15% to −0.03%] per 30-year increment in age), but not for monotherapy (AR, −0.08% [95% CrI, −0.18% to 0.01%]) or triple therapy (AR, −0.01% [95% CrI, −0.06% to 0.05%]). The relative reduction in MACEs with use of SGLT2 inhibitors was greater in older vs younger participants per 30-year increment in age (hazard ratio, 0.76 [95% CrI, 0.62 to 0.93]), and the relative reduction in MACEs with use of GLP-1 receptor agonists was less in older vs younger participants (hazard ratio, 1.47 [95% CrI, 1.07 to 2.02]). There was no consistent evidence for sex × treatment interactions with use of SGLT2 inhibitors and GLP-1 receptor agonists. Conclusions and Relevance The SGLT2 inhibitors and GLP-1 receptor agonists were associated with lower risk of MACEs. Analysis of age × treatment interactions suggested that SGLT2 inhibitors were more cardioprotective in older than in younger people despite smaller reductions in HbA 1c ; GLP-1 receptor agonists were more cardioprotective in younger people.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
monster0101完成签到 ,获得积分10
1秒前
1秒前
酷炫的一笑完成签到,获得积分10
2秒前
完美世界应助GL采纳,获得10
8秒前
9秒前
鸭梨发布了新的文献求助10
9秒前
14秒前
咪呀完成签到,获得积分10
15秒前
etheral发布了新的文献求助10
16秒前
风趣小蜜蜂完成签到 ,获得积分10
16秒前
17秒前
优雅愚志完成签到,获得积分10
17秒前
19秒前
木木应助GL采纳,获得10
19秒前
song发布了新的文献求助10
20秒前
23秒前
负责怀莲发布了新的文献求助10
25秒前
Grandir发布了新的文献求助20
26秒前
28秒前
kami完成签到 ,获得积分10
28秒前
赵欣媛完成签到 ,获得积分10
30秒前
科研通AI5应助Arui采纳,获得10
32秒前
朴实的热狗完成签到,获得积分10
32秒前
mitty完成签到 ,获得积分10
32秒前
黎乐荷发布了新的文献求助10
35秒前
Jasper应助负责怀莲采纳,获得10
35秒前
荔枝完成签到 ,获得积分10
37秒前
今后应助多年以后采纳,获得10
38秒前
43秒前
星辰大海应助song采纳,获得10
44秒前
李爱国应助Grandir采纳,获得20
44秒前
英姑应助黎乐荷采纳,获得10
46秒前
47秒前
48秒前
50秒前
50秒前
经纲完成签到 ,获得积分0
51秒前
51秒前
多年以后发布了新的文献求助10
53秒前
糖果完成签到 ,获得积分10
53秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989949
求助须知:如何正确求助?哪些是违规求助? 3532017
关于积分的说明 11255865
捐赠科研通 3270829
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882233
科研通“疑难数据库(出版商)”最低求助积分说明 809216